Tina D Mahajan1, Ted R Mikuls1,2. 1. Division of Rheumatology, Department of Internal Medicine. 2. Veterans Affairs Nebraska-Western Iowa Healthcare System, University of Nebraska Medical Center, Omaha, NE, USA.
Abstract
PURPOSE OF REVIEW: Therapies for rheumatoid arthritis (RA) continue to expand rapidly. The purpose of this review is to discuss novel treatment options, including biosimilars, that are available, as well as to highlight promising agents in development. The purpose is also to discuss new emerging safety signals associated with these drugs and to discuss strategies in tapering therapy. RECENT FINDINGS: There are several novel RA therapies. These include the interleukin-6 (IL-6) receptor blocker sarilumab, which was approved in 2017. In aggregate, the sarilumab studies show that it is effective in RA, including patients with incomplete responses to methotrexate and anti-tumor necrosis factor inhibitor, and showing superior efficacy when used in higher dose (200 mg every 2 weeks) to standard-dose adalilumab. Other drugs that are currently being studied include the IL-6 cytokine blocker sarikumab, the small targeted molecule filgotinib, and many new biosimilars. Baracitinib failed to achieve approval by the Food and Drug Administration primarily over perceived safety concerns. The two biosimilar drugs currently approved are CT-P13 and SB2, which are based on the reference product infliximab. Although this review summarizes trials examining biologic tapering, additional data are needed to guide clinicians in regards to treatment de-escalation in RA. SUMMARY: With the greatly expanded armamentarium of RA treatment options available, it is important for clinicians to understand the data regarding drug efficacy and safety. With remission increasingly attainable, effective drug tapering strategies are needed. Although tapering trials do exist, more studies will be needed to help guide clinical practice.
PURPOSE OF REVIEW: Therapies for rheumatoid arthritis (RA) continue to expand rapidly. The purpose of this review is to discuss novel treatment options, including biosimilars, that are available, as well as to highlight promising agents in development. The purpose is also to discuss new emerging safety signals associated with these drugs and to discuss strategies in tapering therapy. RECENT FINDINGS: There are several novel RA therapies. These include the interleukin-6 (IL-6) receptor blocker sarilumab, which was approved in 2017. In aggregate, the sarilumab studies show that it is effective in RA, including patients with incomplete responses to methotrexate and anti-tumor necrosis factor inhibitor, and showing superior efficacy when used in higher dose (200 mg every 2 weeks) to standard-dose adalilumab. Other drugs that are currently being studied include the IL-6 cytokine blocker sarikumab, the small targeted molecule filgotinib, and many new biosimilars. Baracitinib failed to achieve approval by the Food and Drug Administration primarily over perceived safety concerns. The two biosimilar drugs currently approved are CT-P13 and SB2, which are based on the reference product infliximab. Although this review summarizes trials examining biologic tapering, additional data are needed to guide clinicians in regards to treatment de-escalation in RA. SUMMARY: With the greatly expanded armamentarium of RA treatment options available, it is important for clinicians to understand the data regarding drug efficacy and safety. With remission increasingly attainable, effective drug tapering strategies are needed. Although tapering trials do exist, more studies will be needed to help guide clinical practice.
Authors: Noortje van Herwaarden; Alfons A den Broeder; Wilco Jacobs; Aatke van der Maas; Johannes W J Bijlsma; Ronald F van Vollenhoven; Bart J F van den Bemt Journal: Cochrane Database Syst Rev Date: 2014-09-29
Authors: Chantal A M Bouman; Aatke van der Maas; Noortje van Herwaarden; Eric H Sasso; Frank H J van den Hoogen; Alfons A den Broeder Journal: Rheumatology (Oxford) Date: 2017-06-01 Impact factor: 7.580
Authors: A Kavanaugh; J Kremer; L Ponce; R Cseuz; O V Reshetko; M Stanislavchuk; M Greenwald; A Van der Aa; F Vanhoutte; C Tasset; P Harrison Journal: Ann Rheum Dis Date: 2016-12-19 Impact factor: 19.103
Authors: T M Kuijper; J J Luime; P H P de Jong; A H Gerards; D van Zeben; I Tchetverikov; P B J de Sonnaville; M V van Krugten; B A Grillet; J M W Hazes; A E A M Weel Journal: Ann Rheum Dis Date: 2016-06-09 Impact factor: 19.103
Authors: Gerd R Burmester; Yong Lin; Rahul Patel; Janet van Adelsberg; Erin K Mangan; Neil M H Graham; Hubert van Hoogstraten; Deborah Bauer; Juan Ignacio Vargas; Eun Bong Lee Journal: Ann Rheum Dis Date: 2016-11-17 Impact factor: 19.103
Authors: Paul Emery; Jiří Vencovský; Anna Sylwestrzak; Piotr Leszczyński; Wieslawa Porawska; Barbara Stasiuk; Joanna Hilt; Zdenka Mosterova; Soo Yeon Cheong; Jeehoon Ghil Journal: Ann Rheum Dis Date: 2017-08-09 Impact factor: 19.103
Authors: Tom W J Huizinga; Roy M Fleischmann; Martine Jasson; Allen R Radin; Janet van Adelsberg; Stefano Fiore; Xiaohong Huang; George D Yancopoulos; Neil Stahl; Mark C Genovese Journal: Ann Rheum Dis Date: 2013-12-02 Impact factor: 19.103
Authors: Tsutomu Takeuchi; Carter Thorne; George Karpouzas; Shihong Sheng; Weichun Xu; Ravi Rao; Kaiyin Fei; Benjamin Hsu; Paul P Tak Journal: Ann Rheum Dis Date: 2017-08-30 Impact factor: 19.103
Authors: Daniel Kuo; Nicolette T Morris; Gurjit S Kaeley; Ami Ben-Artzi; Jenny Brook; David A Elashoff; Veena K Ranganath Journal: Clin Rheumatol Date: 2020-08-15 Impact factor: 2.980
Authors: Marjan Ghiti Moghadam; Femke B G Lamers-Karnebeek; Harald E Vonkeman; Peter M Ten Klooster; Janneke Tekstra; Barbara van Schaeybroeck; Ruth Klaasen; Marieke van Onna; Hein J Bernelot Moens; Henk Visser; Annemarie M Schilder; Marc R Kok; Robert B M Landewé; Piet L C M van Riel; Mart A F J van de Laar; Tim L Jansen Journal: BMC Rheumatol Date: 2019-06-13
Authors: Martin Krusche; Philipp Klemm; Manuel Grahammer; Johanna Mucke; Diana Vossen; Arnd Kleyer; Philipp Sewerin; Johannes Knitza Journal: JMIR Mhealth Uhealth Date: 2020-07-20 Impact factor: 4.773